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http://www.biomedcentral.com/1471-2407/13/374RESEARCH ARTICLE Open AccessScreening for phenotype selective activity in
multidrug resistant cells identifies a novel tubulin
active agent insensitive to common forms of
cancer drug resistance
Mårten Fryknäs1†, Joachim Gullbo1†, Xin Wang3†, Linda Rickardson1, Malin Jarvius1, Malin Wickström1, Saadia Hassan1,
Claes Andersson1, Mats Gustafsson1, Gunnar Westman4, Peter Nygren2, Stig Linder3 and Rolf Larsson1*Abstract
Background: Drug resistance is a common cause of treatment failure in cancer patients and encompasses a multitude
of different mechanisms. The aim of the present study was to identify drugs effective on multidrug resistant cells.
Methods: The RPMI 8226 myeloma cell line and its multidrug resistant subline 8226/Dox40 was screened for cytotoxicity
in response to 3,000 chemically diverse compounds using a fluorometric cytotoxicity assay (FMCA). Follow-up profiling
was subsequently performed using various cellular and biochemical assays.
Results: One compound, designated VLX40, demonstrated a higher activity against 8226/Dox40 cells compared to its
parental counterpart. VLX40 induced delayed cell death with apoptotic features. Mechanistic exploration was
performed using gene expression analysis of drug exposed tumor cells to generate a drug-specific signature. Strong
connections to tubulin inhibitors and microtubule cytoskeleton were retrieved. The mechanistic hypothesis of VLX40
acting as a tubulin inhibitor was confirmed by direct measurements of interaction with tubulin polymerization using a
biochemical assay and supported by demonstration of G2/M cell cycle arrest. When tested against a broad panel of
primary cultures of patient tumor cells (PCPTC) representing different forms of leukemia and solid tumors, VLX40
displayed high activity against both myeloid and lymphoid leukemias in contrast to the reference compound
vincristine to which myeloid blast cells are often insensitive. Significant in vivo activity was confirmed in myeloid U-937
cells implanted subcutaneously in mice using the hollow fiber model.
Conclusions: The results indicate that VLX40 may be a useful prototype for development of novel tubulin active
agents that are insensitive to common mechanisms of cancer drug resistance.
Keywords: Screening, Myeloma cell lines, Primary cultures, Drug resistance, Tubulin inhibitionBackground
Current treatment strategies for treatment of cancer are
limited by the occurrence of drug resistance [1-3]. The
cellular mechanisms have been extensively studied in cell
line models and include alterations of drug transport,
metabolism, DNA synthesis and repair, cell survival and
apoptosis. Both genetic and epigenetic changes may* Correspondence: rolf.larsson@medsci.uu.se
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reproduction in any medium, provided the orbe involved in determining the balance between drug
sensitivity and resistance [4,5]. Consequently, novel ther-
apies avoiding these mechanisms are urgently needed.
During the past decades most screening approaches for
identification of new cancer drug candidates have utilized
cell free assays for detection of specific interactions with
known or emerging molecular targets [6]. However, the
relatively poor outcome with respect to identification of
clinically novel and significantly improved cancer drugs
has led to a renewed and growing interest for cancer drug
screening based on compound induced changes in cellular
phenotypes [7-9]. Cultures of human tumor cell linesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Median IC50 for different diagnoses in response
to VLX40
Diagnosis Median IC50 (μM) Number of samples
Breast cancer >34 8
Colon cancer >34 5
Lung cancer >34 6
Renal cancer >34 8
Ovarian cancer >34 19
AML 1.56 8
ALL 3.21 19
CML 0.98 2
CLL 2.18 11
NHL 0.51 13
PBMC 16.3 4
Fryknäs et al. BMC Cancer 2013, 13:374 Page 2 of 14
http://www.biomedcentral.com/1471-2407/13/374have been the general model in these efforts and are
important tools for predicting mechanisms of drug action
as demonstrated in numerous reports [7,9]. Furthermore,
recent results utilizing very large panels of cell lines
indicate that they also to a large extent retain genomic
features of the primary tumor and can recapitulate
clinical findings with regard to their response to targeted
inhibitors [9].
We have previously utilized the myeloma cell line RPMI
8226 and its multidrug resistant (MDR) 8226/Dox40
subline for phenotype selective activity in response to
an annotated compound library [10]. The 8226/Dox40
subline over expresses P-glycoprotein [11], but also other
mechanisms are likely contributing to the multidrug
resistant phenotype [12]. We have also previously demon-
strated that over expression of STAT1-regulated genes con-
tribute to doxorubicin resistance observed in 8226/Dox40
cells [13,14].
In the present study the same myeloma cell lines were
tested in response to 3,000 chemically diverse compounds
to explore the possibility of finding compounds selectively
active against the MDR phenotype. After hit validation
and counter screening one hit compound, VLX40, was
selected for mechanistic investigation and further preclinical
evaluation.
Methods
Cell culture
For primary screening RPMI 8226 and its multidrug
resistant cell line 8226/Dox40 were used. In a secondary
screen, a cell line panel representing different drug resist-
ance phenotypes was used (described in Table 1). The cell
lines of this panel were cultured and harvested as previously
described [14].
An additional 98 primary cultures of primary human
tumor cells (PCPTCs) from different tumor types, and four
preparations of normal peripheral blood mononuclear cells
(PBMC), detailed in Table 2, were used to determine theTable 1 Cell line panel representing different types of drug re
Cell line Diagnosis Selective agent
RPMI 8226 Myeloma
8226/Dox40 Myeloma Doxorubicin
8226/LR5 Myeloma Melphalan
CCRF-CEM T-cell leukemia
CEM/VM-1 T-cell leukemia Teniposode
NCI-H69 Small cell lung cancer
H69AR Small cell lung cancer Doxorubicin
U-937 Histiocytic lymphoma
U-937-vcr Histiocytic lymphoma Vincristine
*mRNA gene expression, probe ID 209993_at (ABCB1 P-gp), (Affymetrix, Inc.).
**Gene expression not detected, absent call according to MAS5 (Affymetrix, Inc.).activity spectrum of VLX40 and, for comparison, six
standard cytotoxic drugs chosen to represent different
mechanistic classes. The tumor samples were obtained by
bone marrow/peripheral blood sampling, routine surgery
or diagnostic biopsy. Leukemic cells and PBMCs were
isolated by 1.077 g/ml Ficoll-Paque centrifugation [20].
Tumor tissue from solid tumor samples was minced into
small pieces and tumor cells were isolated by collagenase
dispersion followed by Percoll density gradient centrifuga-
tion [21]. The patient sampling was approved by the
Regional Ethics Board, Uppsala, Sweden. Cell viability
was determined by trypan blue exclusion test and the
proportion of tumor cells in the preparation was judged
by inspection of May-Grunwald-Giemsa stained cytospin
slides. All samples used in this study contained more than
70% tumor cells.
The human cell lines used for mechanistic studies were
MCF7 (breast cancer), HCT 116 (colon cancer) and
hTERT-RPE-1 (normal epithelial cell line). MCF7, HCT
116 and HL-60 were obtained from American Type
Culture Collection (ATCC, Rockville, MD) whereassistance
Mechanism of resistance P-gp expression* Reference
82
P-gp170 27002 [11,15]
GSH associated Not expressed** [16]
Not expressed**
Topo II associated Not expressed** [17]
Not expressed**
MRP associated Not expressed** [18]
Not expressed**
Tubulin associated 875 [19]
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in vivo hollow fiber studies the myelocytic cell line U-937
was used. The normal epithelial hTERT-RPE-1 cells were
cultured in Dulbecco’s Modified Eagles Medium nutrient
mixture F-12 Ham, supplemented with 10% heat-inactivated
fetal calf serum, 2 mM glutamine, 100 μg/ml streptomycin
and 100 U/ml penicillin (all from Sigma Aldrich Co, St
Louis, MO) at 37°C in humidified air containing 5% CO2.
MCF-7 was grown in in Eagle’s Minimal Essential Medium,
supplemented as above. HCT116 were grown in complete
McCoy’s medium. RPMI 8226, 8226/Dox40, HL-60 and
U-937 were grown in complete RPMI medium.
Preparation of compounds for screening
The Maybridge Hitskit 3000 library (Maybridge Inc) con-
sists of 3000 chemically diverse compounds. The library
was delivered in 36 racks each containing 80 compounds
dissolved in DMSO to 10 mg/ml. For the screening, ali-
quots of the DMSO solutions were transferred to 96-well
plates and were further diluted with PBS to obtain stock
solutions of 100 μg/ml from which four different 384-well
plates for screening were prepared with final test concen-
trations of 1 μg/ml. In all steps, the Biomek 2000 pipetting
station connected to a plate stacker carousel (Beckman
Coulter Inc, Fullerton, CA) in a safety cabinet (Bigneat Inc,
Hampshire, UK) was used. For dose-response studies,
plates containing VLX40 (Vivolux AB, Uppsala, Sweden)
and other compounds were prepared by 10-fold serial dilu-
tions in the concentrations 0.004 to 40 μM using the same
robotic system. The plates were stored at -70°C until
further use. The screening identified one compound
with higher activity against 8226/Dox40 cells compared to
its parental counterpart RPMI 8226. This compound, chem-
ically a quinoline alkaloid (2-phenyl-4-hydroxyquinoline-6-
carboxylic acid ethyl ester), was designated VLX40, and
subjected for detailed studies.
Measurement of cancer drug activity
The Fluorometric Microculture Cytotoxicity Assay, FMCA,
described in detail previously [22], was used for measure-
ment of the cytotoxic effect of library compounds and
the established standard drugs. The FMCA is based on
measurement of fluorescence generated from hydrolysis
of fluorescein diacetate (FDA) to fluorescein by cells with
intact plasma membranes. Cells were seeded in the drug-
prepared 384-well plates using the pipetting robot Pre-
cision 2000 (Bio-Tek Instruments Inc., Winooski, VT).
The number of cells per well was 2,500 - 5,000 for solid
tumor samples and 10,000 – 20,000 for leukemic samples.
In each plate, two columns without drugs served as
controls and one column with medium only served as
blank.
The plates were incubated for 72 h and then transferred
to an integrated HTS SAGIAN Core System consisting ofan ORCA robot (Beckman Coulter) with CO2 incubator
(Cytomat 2C, Kendro, Sollentuna, Sweden), dispenser
module (Multidrop 384, Titertek, Huntsville, AL), washer
module (ELx 405, Bio-Tek Instruments Inc), de-lidding
station, plate hotels, barcode reader (Beckman Coulter),
liquid handler (Biomek 2000, Beckman Coulter) and a
multipurpose reader (FLUOstar Optima, BMG Labtech
GmbH, Offenburg, Germany) for automated FMCA.
Quality criteria for a successful assay included a mean
coefficient of variation of less than 30% in the control
wells and a fluorescence signal in control wells of more
than 5 times the blank (10 times for cell lines). Survival
index (SI) is defined as the fluorescence of test wells in
percentage of controls with blank values subtracted.
Multiparametric high content evaluation of apoptosis and
cell cycle arrest
The fluorescence microscope ArrayScan High Content
Screening (HCS) system (Cellomics Inc., Pittsburgh, PA,
USA) was used to study apoptosis and cell cycle arrest.
For these assays, cells were seeded into 96-well plates
(PerkinElmer Inc., Wellesley, MA, USA), left to attach
over night, before test compounds were added.
Cell death characteristics were studied using a multi-
parametric HCS assay described in detail previously [23].
Apoptosis was evaluated after 6, 24 and 48 h exposure
to VLX40 in MCF-7 cells. The FLICA probe FAM-
DEVD-FMK (carboxyfluorescein-labeled fluoromethyl
ketone peptide inhibitor of caspase-3; at a final concentra-
tion of 20 μM) was added 1 h before the end of the drug
exposure to stain activated caspase-3/7. Plates were then
washed and nuclei stained with 10 μM Hoechst 33342 in
a fixation solution with 3.7% formaldehyde.
To study cell cycle arrest, HCT116 cells were incubated
for 24 h with VLX40. Cells were stained using Cell Cycle
Kit I reagents for DNA content and phospho-histone H3
staining (Thermo Fisher Scientific) according to the
manufacturer’s instructions. Primary antibodies specific
for phospho-histone H3 (rabbit), secondary antibodies
DyLight 549 Conjugated Goat anti-Rabbit IgG and DAPI
dye were used.
Processed plates were loaded in the ArrayScan and
analyzed. Images were acquired for each fluorescence
channel, using suitable filters with 10X or 20X objective
and in each well at least 1000 cells were analyzed. Quan-
tification of apoptosis was performed by measuring
caspase-3 activation and nuclear fragmentation, wheras
quantification of cell cycle arrest was obtained by nuclear
DNA content (mean average intensity of DAPI) and
phospho-histone H3 (total intensity).
Flow cytometry analysis of cell cycle and apoptosis
Cells were seeded in 24- well plates 24 h prior to treatment
with different concentrations of VLX40 for 6, 16, 24 and
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PBS and stained with Annexin V-FITC according to the
instructions of the vendor (Annexin V-FITC apoptosis de-
tection kit 556547, BD Pharmingen). Cell cycle analysis
was performed by labeling digitonin-permeabilized cells
with 5 ug/ml propidium iodide. Flow cytometry analysis
was performed using a BD LSR II flow cytometer.
Phase contrast microscopy
Time-lapse phase contrast microscopy was performed
using an automated IncuCyte phase contrast microscope
(Essen Instruments, Ann Arbor, MI). MCF-7 cells (10,000/
well) were plated on 24-well ImageLock plates (Essen
Instruments) and immediately placed into the IncuCyte
imaging system. The chamber is designed to fit into a
standard, humidified incubator in an atmosphere of 5%
CO2, and a moving objective allows the cell culture to
be stationary while images are captured at different
positions from well to well. Images were collected at
1 h intervals starting 30 min after placing the plate in
the IncuCyte chamber and cells were left to attach for
24 h when drug treatment was performed. Cell density
(i.e. confluence) was calculated using the IncuCyte
software.
Microarray analysis
RNA from cell cultures was isolated using RNeasy Mini
Kit from Qiagen and immediately stored at -70°C until
further use. RNA purity and quality was measured using
an ND 1000 spectrophotometer (NanoDrop Tecnhologies,
Wilmington, DE) and Bioanalyzer 2100 (Agilent Technolo-
gies Inc, Palo Alto, CA, USA), respectively. Starting from
2 μg of total RNA, gene expression analysis was performed
using Genome U133 Plus 2.0 Arrays according to the
GeneChip Expression Analysis Technical Manual (Rev.
5, Affymetrix Inc., Santa Clara, CA). Raw data was nor-
malized using MAS5 (Affymetrix Inc.). Connectivity
Map (cmap) build 02 (www.broad.mit.edu/cmap) contains
genome-wide expression data for 1,309 compounds (6,100
entries, including replicates, different doses and cell lines).
The original protocol using MCF-7 breast cancer cells as
described by Lamb et al. was used [24]. Briefly, cells were
seeded in a 6-well plate at a density of 0.4 × 106 cells
per well. Cells were left to attach for 24 h, followed by
exposure to either VLX40 at a final concentration of
10 μM, or to vehicle control (DMSO). After 6 h the cells
were washed with PBS and total RNA was prepared. Gene
expression ratios for drug treated vs. control cells were
calculated to generate a list of regulated genes. This list
was further filtrated using the flags from the MAS5
normalization. Only probes with signals over 300 arbitrary
units and present call in both VLX40 treated and vehicle
control were used in the Gene Set Enrichment Analysis
(GSEA). In the cmap analysis, only probes present on HGU133A were used, for cmap compatibility. The 20 most
up and the 10 most down regulated genes (i.e. probes)
were uploaded into the cmap and compared to the 6,100
instances in the cmap database, to retrieve a list of
compounds with similar response profile as VLX40. The
GSEA software and method for microarray result explor-
ation has been described elsewhere [25]. Briefly, the
pre-ranked list (VLX40 exposed MCF-7 cells vs. untreated
control, described above) was compared to a priori
defined and curated gene sets (C2). The p-value refers to
the nominal p-value after 1000 permutations.
Measurements of tubulin polymerization
Tubulin polymerization from purified tubulin monomers
was measured as increased fluorescence because of the
incorporation of a fluorescent reporter into growing
microtubules. All reagents necessary for performing the
assay were provided in the kit BK011 from Cytoskeleton
(Denver, Colorado, USA). The fluorescence was measured
at 1-min intervals for 60 min using a FLUOstar Optima
(BMG Labtech GmbH, Offenburg, Germany).
Immunological assays
Spheroids produced by the hanging drop method in 96
well plates were fixed in paraformaldehyde, dehydrated,
embedded in paraffin and sectioned and stained for Ki67
and active caspase-3, as previously described [26].
In vivo studies
Myeloid U-937 cells were cultured inside semi-permeable
polyvinylidene fluoride fibers and assessed in the hollow
fiber assay [27,28]. The fibers were implanted subcutane-
ously into the back of immunocompetent animals (male
NMRI mice, Scanbur, Sollentuna Sweden). The following
day each mouse was treated with a single subcutaneous
injection of VLX40 at a dose of either 0.5 μmol/animal
(n = 8), 2 μmol/animal (n = 8), or vehicle (n = 8). Fibers were
retrieved after 6 days and cell density evaluated using the
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide)-assay [29]. The method is based on the conver-
sion of MTT to blue formazan crystals by living cells. The
formazan was extracted by DMSO as previously described
[28], and optical density (OD) read at 570 nm. Cell density
for each fiber on retrieval day was expressed as net
growth, defined as (OD retrieval day – OD implantation
day)/OD implantation day × 100, i.e. the percent change
in cell density in the fibers during the 6 days of in vivo
experiment. The animals were observed regarding behavior
and weight gain throughout the experiment. 200 μl blood
samples were obtained through the orbital plexus after
anesthetization with isofluran just before euthanasia,
and analyzed for hematological parameters. Animals were
caged four in each cage and fed a commercial diet
(Lactamin AB, Sweden), with water given ad libitum. The
Fryknäs et al. BMC Cancer 2013, 13:374 Page 5 of 14
http://www.biomedcentral.com/1471-2407/13/374study was approved by the Animal Ethics Committee in
Uppsala, Sweden.
Data analysis and statistics
Screening data was exported to Vortex (Dotmatics Inc,
UK) software for analysis. A Survival Index of less than 50%
in myeloma 8226/Dox40 and more than 50% in parental
RPMI 8226 cells was set as the criteria for qualifying as a
hit compound.
Concentration-response data of screening hits and
standard agents were analyzed using the software
GraphPadPrism4 (GraphPad Software Inc., San Diego, CA,
USA). Data was processed using non-linear regression
to a standard sigmoidal dose-response model to obtain
IC50-values (the concentration resulting in a SI of 50%).
Response rate in PCPTCs of a specific diagnosis was
defined as the fraction of samples having an SI below
the median, calculated from all PCPTSs included in the
study, at the drug concentration showing the largest SD in
survival (SI). For VLX40 this concentration was 3.4 μM.
The data for the reference compound vincristine was
taken from Lindhagen et al [30], and recalculated as
response rate at 1 μM. The PCPTC samples used are
listed in Table 2. The relative effect of a drug on solid
compared with hematological tumors was indicated by
the S/H ratio, defined as the ratio between the total re-
sponse rates for the solid and the hematological samples.
Tumor cell specific activity was estimated by calculation of
the ratio of the median IC50-value for PBMC over that of
chronic lymphocytic leukemia (CLL) samples. Comparisons
between groups in the hollow fiber experiment were done
with Student’s t-test.
Results
Drug screening using multidrug-resistant myeloma cells
We here used 8226/Dox40 myeloma cells as a model
for drug resistance. Multiple mechanisms, including over-
expression of P-glycoprotein, have been shown to contribute
to the drug resistant phenotype [11-14]. A library of 3,000
chemically diverse compounds was used for screening
of 8226/Dox40 and parental RPMI 8226 cells at a concen-
tration of 1 μg/ml, and cytotoxic/antiproliferative activity
was determined using FMCA (Figure 1A). One compound,
RH02104 (Figure 1B) (subsequently denoted VLX40), dem-
onstrated phenotype selective activity for the 8226/Dox40
subline.
A cell line panel of different origins, characterized by
different mechanisms of drug resistance (Table 1), was
tested for its sensitivity to VLX40 at 1 μg/ml. We found
that VLX40 was not sensitive to multidrug resistance
protein (MRP)- or topoisomerase II (Topo II)-mediated
drug resistance (Figure 1C). Furthermore, the U-937/vcr
cell line, associated with resistance to tubulin inhibitors,
was almost as sensitive to VLX40 as parental U-937cells (Figure 1C). Finally, immortalized human epithelial
hTERT-RPE-1 cells were less sensitive to VLX40 at 1 μg/ml.
Further hit confirmation in extended dose-response
testing of VLX40 confirmed the relatively higher sensitiv-
ity of 8226/Dox40 compared to parental RPMI 8226
(Figure 1D), the difference in IC 50 being statistically
significant (P < 0.05, Students t-test). In contrast, 8226/
Dox40 cells are highly resistant to vincristine (Figure 1E).
Based on these findings VLX40 was selected for further
preclinical evaluation.
VLX40 induces apoptosis in cancer cells
We examined the response of both solid and hematological
tumor cells to VLX40 (see further below). The response
of the breast cancer cell line MCF-7 was studied using
time-lapse phase contrast microscopy and multi-parameter
analysis for cell death using Array Scan (Figure 2). A
concentration-dependent effect on cell proliferation was
observed (Figure 2A). Phase contrast images of treated
cells showed a rounded-up morphology surrounded by a
bright halo (Figure 2B). No increase in membrane perme-
ability was observed at 6 h, whereas increases were
observed at 24 and 48 h (Figure 2C). In parallel, we
observed an increase in DNA fragmentation and caspase-
3-like activity (using a DEVD-based substrate) at 24 and
48 h (Figure 2D and E).
Induction of apoptosis was confirmed by analysis of
annexin V/propidium iodide staining (Figure 2F) in
myeloma and myeloid leukemia cell lines (Figure 2F).
RPMI 8226 and 8226/Dox40, U-937 and HL-60 cells were
exposed to VLX40 for 24 hrs, stained and analysed by flow
cytometry. Apoptosis was found to be reduced by inhibi-
tors of caspase-3 and caspase-9, showing involvement of
the intrinsic apoptosis pathway (Figure 2G).
Identification of VLX40 as a tubulin active agent
Mechanistic exploration was performed by measurement
of gene expression of drug treated tumor cell cultures
(Figure 3). The breast cancer cell line MCF-7 was exposed
to 10 μM VLX40 or vehicle (DMSO) for 6 hours followed
by microarray-based gene expression analysis. A drug spe-
cific query signature was generated and uploaded to the
Connectivity Map (cmap), to find other compounds
with similar mechanism of action. The VLX40 signa-
ture showed strongest similarity to known tubulin in-
hibitors such as fenbendazole, vinblastine, nocodazole
and podophyllotoxin. In fact, all of the top seven com-
pounds are tubulin inhibitors (Figure 3A) [31-34]. Gene set
Enrichment analysis (GSEA) of genes induced by VLX40
showed significant association to mitosis (Figure 3B)
VLX40 induced a strong increase in phospho-histone H3
(Figure 3C) indicative of inhibition of mitosis and further
cell cycle analysis demonstrated clear G2/M arrest in RPMI
8226 and 8226/Dox40 as well as in myeloid U-937 and
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http://www.biomedcentral.com/1471-2407/13/374HL-60 cells using flow cytometry (Figure 3D). The
mechanistic hypothesis of VLX40 causing tubulin inhib-
ition was subsequently confirmed by measuring tubulin
polymerization in vitro. In this cell free assay bothVLX40 and the reference compound vincristine (3 μM)
clearly inhibited tubulin polymerization whereas paclitaxel
(3 μM), as expected, increased polymerization activity
(Figure 3E).
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Figure 2 VLX40 induces apoptosis in the MCF-7 breast cancer cell line. In panel (A) cell growth kinetics were determined every hour during
culture of MCF-7 tumor cells in 24-well plates. Cell confluence was determined by phase contrast time-lapse microscopy using an automated
IncuCyte system. Representative phase contrast photomicrographs of control and VLX40 (10 μM) exposed cultures after 72 h are shown in panel
(B). Using Array Scan II the effects of VLX40 on membrane permeability (C), DNA fragmentation (D) and caspase-3/7 activity (E) were evaluated
and are shown over time (6-24 h). The results are expressed as percentage of the untreated control and presented as mean values + SEM from
three independent experiments. Flow cytometry analysis of annexin V (x-axis) and propidium iodide (Y-axis) stained cells after 48 hrs exposure to
VLX 40 in RPMI 8226 S, 8226/Dox40, U-937 and HL-60 cells (F). In (G) the effect of VLX40 with and without caspase inhibitors DEVD-FMK and
LEHD-FMK on annexin V staining is shown in U-937 cells.
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To examine the activity spectrum of VLX40, its cytotoxic
effect was studied in 96 samples of primary cancer patient
tumor cells (PCPTC) from patients with a variety of solid
tumors and hematological malignancies as well as in
four samples of primary lymphocytes from healthy donors
(PBMC). Median IC50-values ranged from < 1 μM for
diagnoses such as chronic lymphocytic leukemia (CLL),
acute lymphocytic leukemia (ALL), acute myelocytic
leukemia (AML), chronic myelocytic leukemia (CML)
and lymphoma to > 34 μM for breast, ovarian, colon, lung
and renal cancer samples (Table 2). PBMC displayed inter-
mediate sensitivity to VLX40. The in vitro response rates
to VLX40 at 3.4 μM for the PCPTC of various diagnoses
is displayed in Figure 4A. Consistent with the IC50 pat-
terns in cell lines, leukemic malignancies showed the
highest response rates followed by ovarian carcinoma and
breast cancer whereas colon and renal cancer demon-
strated the lowest response rates. Vincristine was included
as a reference compound demonstrating a similar activity
spectrum with lymphocytic leukemias being most
sensitive. However, myelocytic leukemias were clearly less
sensitive to vincristine, contrasting the high in vitro
response rate obtained with VLX40.
The relative effect of VLX40 and six standard cytotoxic
drugs, in solid and hematological tumor samples, expressed
as the solid/hematological (S/H) ratio is shown in Figure 4B.
VLX40 had a ratio of 0.28 indicating a modest activity
against solid tumors compared to cisplatin (S/H ratio 1.2).
All the remaining drugs showed S/H ratios < 0.5. The
results for the standard drugs are consistent with their main
clinical use. To roughly estimate tumor cell specificity,
drug effects were compared in cells from CLL and normal
PBMCs. VLX40 demonstrated a significantly higher activity
against the malignant phenotype with a PBMC/CLL
median IC50 ratio of 12.2 (Figure 4C). Of the tested
standard cytotoxic drugs only vincristine was more active
in CLL than in PBMC.
To further evaluate and explain the relatively low
activity of VLX40 on PCPTCs from solid tumors, which
consists of multicellular clusters [21], we examined the
ability of the compound to induce apoptosis of colon
cancer cells grown as multicellular spheroids. As shown
in Figure 4D, VLX40 showed a modest ability to induceapoptosis of cells in spheroids as evidenced by caspase-3
positive cells being mostly present in outer cell layers.
The pattern was similar to that observed with vincristine
(Figure 4D).
VLX40 significantly inhibits in vivo growth of myeloid
U-937 cells
In vivo activity of VLX40 was investigated in hollow fiber
cultures of myeloid U-937 cells subcutaneously implanted
in mice (Figure 5). After a single dose of VLX40 (2 μmol/
animal) significant (p < 0.05) growth inhibition and tumor
regression compared to vehicle treatment was observed.
VLX40 showed no signs of toxicity at the doses tested.
Discussion
Genomics-based target identification and screening using
cell free systems has been the dominating principle in
cancer drug discovery during the recent decade [6]. As an
alternative to this approach the use of phenotype-cell-based
screening may provide some distinct advantages [35].
We here performed a conditional screen with the aim of
identifying compounds that are cytotoxic to multidrug
resistant myeloma cells. A chemically diverse compound
library was used for this purpose. The screening hit
RH02104/VLX40 was the only compound that fulfilled the
pre-determined criteria of a SI less than 50% in myeloma
8226/Dox40 and more than 50% in parental RPMI 8226
cells. In validation experiments VLX40 was found the
difference was, albeit statistically significant, small. It
can not be excluded that subtle differences in drug uptake
and proliferation characteristics of the cell lines, not
related to drug transporters, could contribute to the
difference observed.
For exploration of mechanisms of action we used a
bioinformatic approach using a drug specific gene expres-
sion signature to probe the cmap database [24]. The results
indicated strong connections to tubulin-active agents. In
vitro assays subsequently confirmed that VLX40 inhibits
the polymerization of tubulin monomers and induces
mitotic arrest.
A large number of tubulin active agents have been
described in the literature, and some of these are important
clinically used agents [36]. The majority of known tubulin
inhibitors are natural products from many classes of
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Figure 3 (See legend on next page.)
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Figure 3 VLX40 is a tubulin active agent. (A) Microarray based mechanistic evaluation using Connectivity Map (cmap). MCF-7 cells were
exposed to VLX40 for 6 h as described in experimental procedures. Out of the 6100 drug specific profiles in the data base, the eight most similar
were all derived from compounds known to be tubulin inhibitors. 5252917 corresponds to N-(2-benzooxazol-2-yl-phenyl)-4-methyl-
benzenesulfonamide. Score according to cmap data base. (B) Gene Set Enrichment Analysis (GSEA) shows significant up-regulation of genes
involved in mitosis. The pre-ranked gene list (VLX40 exposed MCF-7 cells vs. untreated control) was compared to a priori defined and curated
gene sets. The purpose of GSEA is to find out whether the a priori defined gene sets are significantly enriched towards the upper or lower end
of the pre-ranked list. The p-value refers to the nominal p-value after 1000 permutations. (C) Phospho-histone H3 staining using Arrayscan VTI
(total intensity) after exposure to VLX40 for 24 hrs in HCT 116 cells. (D) Analysis of cell cycle distribution after 24 hrs exposure to VLX40 in DAPI
stained RPMI 8226, 8226/Dox40, U-937 and HL-60 cells. (E) Confirmation of tubulin inhibition as the mechanism of action of VLX40 using a cell
free assay for tubulin polymerization. Vincristine (3 μM) and paclitaxel (3 μM) were used as reference compounds.
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Figure 4 Ex vivo activity pattern of VLX40. (A) The ex vivo response rate in a panel of primary cultures of patient tumor cells (PCPTC)
representing a range of diagnoses (n = 98) is shown. The concentrations used were 3.4 μM of VLX40 and 1 μM of vincristine. See material and
methods for details. (B) The solid tumor/hematological tumor activity ratio (S/H ratio) is displayed for VLX40 and six standard agents (n = 99).
(C) The IC50 ratio between CLL (n = 9) and PBMC (n = 4) is shown for VLX40 and six standard drugs. (D) Caspase-3 induction in multicellular
spheroids prepared from HCT116 colon carcinoma cells. Multicellular spheroids were treated for 24 h, fixed, sectioned and stained for active
caspase-3. Note the induction of apoptosis preferentially at peripheral cell layers.
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target by evolution at several independent occasions
[36,37]. Interestingly, microtubule inhibitors have turned
out to be significantly more successful in clinical practice
compared to more recently developed mitosis-specific
agents [38]. It has been suggested that the superior clinical
efficacy of tubulin inhibitors is due to disruption of the
function of microtubules in interphase cells [38].
Investigators have reported that microtubule inhibitors
were identified in screens aimed to identify compounds
directed at other targets, such as kinases [39], suggesting
that tubulin polymerization may be a sensitive process
that is easily targeted by a variety of chemical substances.
Indeed, identification of tubulin inhibitors in screening
diverse chemical libraries is not a rare event [26,40].
Nevertheless VLX40 showed a favorable pharmacological
profile compared to vincristine being active against a
multidrug resistant myeloma cell line with little sensitivity
to other common forms of vinca alkaloid resistance.
VLX40 demonstrated a relatively narrow spectrum of
activity in PCPTCs of various tumor types demonstrating
activity preferentially in leukemias and lymphomas. Using
PCPTCs with FMCA has demonstrated the ability to
reflect tumor-type specific activity (25) as well as providing
good clinical correlations (15,16). The spectrum of
anti-leukemic activity was clearly distinct of that observedfor vincristine; the largest difference being observed for
AML cells which were sensitive to VLX40 but insensitive
to vincristine. This spectrum of vinca alkaloid activity
closely corresponds to clinical activity [30]. In contrast,
VLX40 showed very limited activity on ex vivo solid tumor
cells from breast, ovary, lung, colon and renal cancer
patients. The reason for the low activity observed in the
PCPTC solid tumor models may, at least partly, be due a
to poor drug penetration in the latter model system,
consisting of multicellular clusters [21]. This was sup-
ported by the modest antitumor activity obtained in the
3-D spheroid model cell line. However, in addition to
poor penetration into the deeper cell layers also limited
sensitivity and low proliferation of cells in these layers
could contribute to the low solid tumor activity observed.
8226/Dox40 were originally selected for resistance to
doxorubicin and show cross-resistance to mitoxantrone,
acronycine, etoposide, and vincristine [11,15]. The resistant
subline strongly overexpresses the MDR1 gene product
P-gp170 [11,15]. A study using expression microarrays has
confirmed MDR1 mRNA overexpression and also showed
down-regulation of a number of apoptotic-regulators, in-
cluding caspase-3, the proapoptic regulator BAD and
TNF-receptors [12]. We have reported upregulation of
STAT1-regulated genes in the 8226/Dox40 cell line [13,14].
While P-gp170 is clearly involved in vincristine resistance
Fryknäs et al. BMC Cancer 2013, 13:374 Page 12 of 14
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in the resistance of 8226/Dox40 to vincristine is more
uncertain.
The high PBMC/CLL IC50 ratio indicates a potentially
high therapeutic index ex vivo. It should be emphasized
that both the PBMC/CLL ratio and S/H ratios are in vitro
indicators for therapeutic index and clinical activity
spectra and should be evaluated in relative rather than
absolute terms. A ratio of 1 indicates equal sensitivity
for PBMC vs. CLL and solid vs hematological activity,
respectively. Thus, comparing and ranking different drugs
with respect to these measures is a preferable way to
utilize these indices. Indeed, the S/H index has previously
been shown to correlate well to the clinical activity profile
of standard cytotoxic cancer agents [41]. Both CLL and
PBMC are largely non-proliferative under the present
assay conditions. Furthermore, supporting these ex vivo
findings VLX40 had significant in vivo activity against
myeloid U-937 cells with no signs of toxicity. It should be
noted that the hollow fiber is a very resistant in vivo tumor
model requiring the drug to penetrate into fibers im-
planted deep subcutaneously, thus yielding a low false
positive rate for cancer activity in vivo compared with
other in vivo models [40]. However, the relatively low
solubility of VLX40 in standard vehicles unfortunately
limits the maximum dose that can be administered.
Further work on improved formulations or analogue
development may provide a potential future solution
to this obstacle.
Chemically VLX40 is described as a 2-phenyl-4-hydro-
xyquinoline, which is a flavone-like element that has been
used in medicinal chemistry previously, for example to
design inhibitors of bacterial cell membrane pumps [42],
or to inhibit cyclo-oxygenases [43]. Indeed several reports
also demonstrate antiproliferative effects on human
cancer cells, often as 2-phenyl-4-quinolones (isomers of 2-
phenyl-4-hydroxyquinolines). For example, Hadjeri and
co-workers synthesized a series of 5-hydroxy-2-phenyl-4-
quinolones with potent antiproliferative activity in the
NCI 60 cell line panel, and induced G2/M cell cycle arrest.
Interestingly, the presence of a 5-hydroxy group (not
present in VLX40) appeared to be important for these
antiproliferative effects, which were not associated with
microtubule inhibition [44]. However, others have shown
that 2-phenyl-4-quinolones indeed do posses antimitotic
activities, and that there is a good correlation between
cytotoxicity of these compounds and their ability to inhibit
tubulin polymerization [45-48].
The 2-phenyl-4-hydroxyquinolines are structurally
unrelated to other tubulin inhibitors and may thus display
other characteristics of importance for successful treatment,
like spectrum of side effects or resistance. For example,
vincristine is a substrate for both MRP and P-gp170, while
VLX40 appears un-affected to both these mechanisms(Figure 1C). Furthermore, myeloblasts are often inherently
resistant to vincristine, a feature that has been attributed
to their high myeloperoxidase activity and generation of
hydrogen peroxide by oxidation of hypochlorus acid
subsequently leading to vinca alkaloid degradation [49].
The results of this study confirm the inherent resistance
of AML cells to vincristine (Figure 4A), but not to the
structurally different VLX40.
Conclusions
In conclusion, the present study identified a novel tubulin
active agent with retained activity in multidrug resistant
models and which is active also against myeloid leukemia.
VLX40 has a potential use as a cancer agent by virtue of
its activity on drug resistant cells and may potentially be
developed as an agent for AML. Further preclinical devel-
opment will be required to evaluate its potential role as a
novel prototype for future treatment of malignant diseases.
Competing interests
JG, GW, PN and RL are co-founders and minor share-holders, MF and SL are
minor share-holders, of Vivolux AB.
Authors’ contributions
All authors were involved in designing experiments and interpreting data.
MF, JG and and XW participated in most of the experiments and contributed
equally to this work. RL, PN and SL have been involved in the overall design
of the study and drafting major parts of the manuscript. MW and MJ
performed the arrayscan experiments. LR designed and performed the
primary screen. CA and MG created the screening database structure and
provided bioinformatic support. SH performed the in vivo hollow fiber assay.
GW contributed to the chemical aspects of the study with his expertise in
medicinal chemistry. All authors read and approved the final manuscript.
Acknowledgements
We are grateful for all the work with microarray array analysis at the Uppsala
Expression Array Platform. The skillful technical assistance of Christina Leek
and Lena Lenhammar is gratefully acknowledged. This study was supported
by the Swedish Cancer Society (S.L., P.N., and R.L.), Radiumhemmets
forskningsfonder and the Swedish Research Council (S.L.) and the Lions
Cancer Research Fund (P.N. and R.L.).
Author details
1Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala
University, S-751 85 Uppsala, Sweden. 2Department of Oncology, Radiology
and Clinical Immunology, Uppsala University, S-751 85 Uppsala, Sweden.
3Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska
Institute, Stockholm, Sweden. 4Department of Chemical and Biological
Engineering, Chalmers University of Technology, S-412 96 Gothenburg,
Sweden.
Received: 31 May 2013 Accepted: 24 July 2013
Published: 6 August 2013
References
1. Hait WN, Yang JM: Clinical management of recurrent breast cancer:
development of multidrug resistance (MDR) and strategies to
circumvent it. Semin Oncol 2005, 32(6 Suppl 7):S16–21.
2. Kavallaris M, Annereau JP, Barret JM: Potential mechanisms of resistance
to microtubule inhibitors. Semin Oncol 2008, 35(3 Suppl 3):S22–27.
3. Ling V: Multidrug resistance: molecular mechanisms and clinical
relevance. Cancer Chemother Pharmacol 1997, 40(Suppl):S3–8.
4. Fodale V, Pierobon M, Liotta L, Petricoin E: Mechanism of cell adaptation:
when and how do cancer cells develop chemoresistance? Cancer J 2011,
17(2):89–95.
Fryknäs et al. BMC Cancer 2013, 13:374 Page 13 of 14
http://www.biomedcentral.com/1471-2407/13/3745. Lu H-P, Chao CCK: Cancer cells acquire resistance to anticancer drugs: an
update. Biomed J 2012, 35(6):464–472.
6. Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M: High-
throughput screening: update on practices and success. J Biomol Screen
2006, 11(7):864–869.
7. Dhar S, Gullbo J, Nilsson K, Nygren P, Larsson R: A Nonclonogenic
Cytotoxicity Assay Using Primary Cultures of Patient Tumor Cells for
Anticancer Drug Screening. J Biomol Screen 1998, 3(3):207–216.
8. Hart CP: Finding the target after screening the phenotype. Drug Discov
Today 2005, 10(7):513–519.
9. Sharma SV, Haber DA, Settleman J: Cell line-based platforms to evaluate
the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer
2010, 10(4):241–253.
10. Rickardson L, Fryknas M, Haglund C, Lovborg H, Nygren P, Gustafsson MG,
Isaksson A, Larsson R: Screening of an annotated compound library for
drug activity in a resistant myeloma cell line. Cancer Chemother
Pharmacol 2006, 58(6):749–758.
11. Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ:
Elimination of chemoresistant multiple myeloma clonogenic colony-
forming cells by combined treatment with a plasma cell-reactive
monoclonal antibody and a P-glycoprotein-reactive monoclonal
antibody. Cancer Res 1989, 49(17):4829–4834.
12. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE:
cDNA microarray analysis of multidrug resistance: doxorubicin selection
produces multiple defects in apoptosis signaling pathways. J Pharmacol
Exp Ther 2001, 299(2):434–441.
13. Fryknas M, Dhar S, Oberg F, Rickardson L, Rydaker M, Goransson H,
Gustafsson M, Pettersson U, Nygren P, Larsson R, et al: STAT1 signaling is
associated with acquired crossresistance to doxorubicin and radiation in
myeloma cell lines. Int J Cancer 2007, 120(1):189–195.
14. Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, Nygren P,
Gustafsson MG, Larsson R, Isaksson A: Identification of molecular
mechanisms for cellular drug resistance by combining drug activity and
gene expression profiles. Br J Cancer 2005, 93(4):483–492.
15. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman
HJ, Pinedo HM, Salmon SE: Immunohistochemical detection and
quantitation of P-glycoprotein in multiple drug-resistant human
myeloma cells: association with level of drug resistance and drug
accumulation. Blood 1989, 73(3):747–752.
16. Mulcahy RT, Bailey HH, Gipp JJ: Up-regulation of gamma-glutamylcyateine
synthtase activity in melphalan-resitant human multiple myeloma cells
expressing increased glutathione levels. Cancer Chemother Pharmacol
1994, 34:67–71.
17. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP,
Trent JM: Pharmacological, molecular, and cytogenetic analysis of
“atypical” multidrug-resistant human leukemic cells. Cancer Res 1987,
47(20):5455–5460.
18. Mirski SE, Gerlach JH, Cole SP: Multidrug resistance in a human small cell
lung cancer cell line selected in adriamycin. Cancer Res 1987,
47(10):2594–2598.
19. Botling J, Liminga G, Larsson R, Nygren P, Nilsson K: Development of
vincristine resistance and increased sensitivity to cyclosporin A and
verapamil in the human U-937 lymphoma cell line without overexpression
of the 170-kDa P-glycoprotein. Int J Cancer 1994, 58(2):269–274.
20. Larsson R, Kristensen J, Sandberg C, Nygren P: Laboratory determination of
chemotherapeutic drug resistance in tumor cells from patients with
leukemia, using a fluorometric microculture cytotoxicity assay (FMCA).
Int J Cancer 1992, 50(2):177–185.
21. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P:
Cytotoxic drug sensitivity testing of tumor cells from patients with
ovarian carcinoma using the fluorometric microculture cytotoxicity assay
(FMCA). Gynecol Oncol 1994, 54(2):163–170.
22. Lindhagen E, Nygren P, Larsson R: The fluorometric microculture cytotoxicity
assay. Nat Protoc 2008, 3(8):1364–1369.
23. Lovborg H, Nygren P, Larsson R: Multiparametric evaluation of apoptosis:
effects of standard cytotoxic agents and the cyanoguanidine CHS 828.
Mol Cancer Ther 2004, 3(5):521–526.
24. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J,
Brunet JP, Subramanian A, Ross KN, et al: The Connectivity Map: using
gene-expression signatures to connect small molecules, genes, and
disease. Science 2006, 313(5795):1929–1935.25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette
MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set
enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci USA 2005,
102(43):15545–15550.
26. Fayad W, Rickardson L, Haglund C, Olofsson MH, D’Arcy P, Larsson R, Linder
S, Fryknas M: Identification of agents that induce apoptosis of
multicellular tumour spheroids: enrichment for mitotic inhibitors with
hydrophobic properties. Chem Biol Drug Des 2011, 78(4):547–557.
27. Friberg LE, Hassan SB, Lindhagen E, Larsson R, Karlsson MO:
Pharmacokinetic-pharmacodynamic modelling of the schedule-
dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre
model. Eur J Pharm Sci 2005, 25(1):163–173.
28. Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K, Larsson R:
Determination of drug effect on tumour cells, host animal toxicity and
drug pharmacokinetics in a hollow-fibre model in rats. Cancer Chemother
Pharmacol 2000, 46(6):493–500.
29. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH,
Currens MJ, Seniff D, Boyd MR: Evaluation of a soluble tetrazolium/
formazan assay for cell growth and drug sensitivity in culture using
human and other tumor cell lines. Cancer Res 1988, 48(17):4827–4833.
30. Haglund C, Aleskog A, Nygren P, Gullbo J, Hoglund M, Wickstrom M,
Larsson R, Lindhagen E: In vitro evaluation of clinical activity and toxicity
of anticancer drugs using tumor cells from patients and cells
representing normal tissues. Cancer Chemother Pharmacol 2012,
69(3):697–707.
31. Friedman PA, Platzer EG: Interaction of anthelmintic benzimidazoles and
benzimidazole derivatives with bovine brain tubulin. Biochim Biophys
Acta 1978, 544(3):605–614.
32. Jordan MA, Thrower D, Wilson L: Effects of vinblastine, podophyllotoxin
and nocodazole on mitotic spindles. Implications for the role of
microtubule dynamics in mitosis. J Cell Sci 1992, 102(Pt 3):401–416.
33. Koeller KM, Haggarty SJ, Perkins BD, Leykin I, Wong JC, Kao MC, Schreiber
SL: Chemical genetic modifier screens: small molecule trichostatin
suppressors as probes of intracellular histone and tubulin acetylation.
Chem Biol 2003, 10(5):397–410.
34. Panzer A, Joubert AM, Bianchi PC, Hamel E, Seegers JC: The effects of
chelidonine on tubulin polymerisation, cell cycle progression and
selected signal transmission pathways. Eur J Cell Biol 2001, 80(1):111–118.
35. Root DE, Flaherty SP, Kelley BP, Stockwell BR: Biological mechanism
profiling using an annotated compound library. Chem Biol 2003,
10(9):881–892.
36. Hamel E: Antimitotic natural products and their interactions with tubulin.
Med Res Rev 1996, 16(2):207–231.
37. Giannakakou P, Sackett D, Fojo T: Tubulin/microtubules: still a promising
target for new chemotherapeutic agents. J Natl Cancer Inst 2000,
92(3):182–183.
38. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T: Mitosis is not a key target
of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011,
8(4):244–250.
39. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, Penhallow B,
Markwalder J, He L, Attar RM, Lin TA, et al: Identification of a nonkinase
target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther
2008, 7(11):3490–3498.
40. Yang WS, Shimada K, Delva D, Patel M, Ode E, Skouta R, Stockwell BR:
Identification of Simple Compounds with Microtubule-Binding Activity
That Inhibit Cancer Cell Growth with High Potency. ACS Med Chem Lett
2012, 3(1):35–38.
41. Fridborg H, Jonsson E, Nygren P, Larsson R: Relationship between
diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells
ex vivo and in the clinic. Eur J Cancer 1999, 35(3):424–432.
42. Sabatini S, Gosetto F, Manfroni G, Tabarrini O, Kaatz GW, Patel D, Cecchetti V:
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)
quinoline derivatives as potent inhibitors of the S. aureus NorA efflux
pump. J Med Chem 2011, 54(16):5722–5736.
43. Liao CH, Chang YL, Guh JH, Kuo SC, Huang LJ, Teng CM: Effect of a potent
cyclooxygenase inhibitor, 5-ethyl-4-methoxy-2-phenylquinoline (KTC-5),
on human platelets. J Pharm Pharmacol 2002, 54(7):967–974.
44. Hadjeri M, Peiller EL, Beney C, Deka N, Lawson MA, Dumontet C, Boumendjel
A: Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones.
J Med Chem 2004, 47(20):4964–4970.
Fryknäs et al. BMC Cancer 2013, 13:374 Page 14 of 14
http://www.biomedcentral.com/1471-2407/13/37445. Kuo SC, Lee HZ, Juang JP, Lin YT, Wu TS, Chang JJ, Lednicer D, Paull KD, Lin
CM, Hamel E, et al: Synthesis and cytotoxicity of 1,6,7,8-substituted
2-(4′-substituted phenyl)-4-quinolones and related compounds:
identification as antimitotic agents interacting with tubulin.
J Med Chem 1993, 36(9):1146–1156.
46. Li L, Wang HK, Kuo SC, Wu TS, Lednicer D, Lin CM, Hamel E, Lee KH:
Antitumor agents. 150. 2′,3′,4′,5′,5,6,7-substituted 2-phenyl-4-quinolones
and related compounds: their synthesis, cytotoxicity, and inhibition of
tubulin polymerization. J Med Chem 1994, 37(8):1126–1135.
47. Xia Y, Yang ZY, Xia P, Bastow KF, Nakanishi Y, Nampoothiri P, Hamel E,
Brossi A, Lee KH: Antitumor agents. Part 226: synthesis and cytotoxicity of
2-phenyl-4-quinolone acetic acids and their esters. Bioorg Med Chem Lett
2003, 13(17):2891–2893.
48. Xia Y, Yang ZY, Xia P, Bastow KF, Tachibana Y, Kuo SC, Hamel E, Hackl T,
Lee KH: Antitumor agents. 181. Synthesis and biological evaluation of
6,7,2′,3′,4′-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new
class of antimitotic antitumor agents. J Med Chem 1998, 41(7):1155–1162.
49. Ozgen U, Savasan S, Stout M, Buck S, Ravindranath Y: Further elucidation
of mechanism of resistance to vincristine in myeloid cells: role of
hypochlorous acid in degradation of vincristine by myeloperoxidase.
Leukemia 2000, 14(1):47–51.
doi:10.1186/1471-2407-13-374
Cite this article as: Fryknäs et al.: Screening for phenotype selective
activity in multidrug resistant cells identifies a novel tubulin active
agent insensitive to common forms of cancer drug resistance. BMC
Cancer 2013 13:374.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
